• Product nameAnti-CLCN2 antibody
    See all CLCN2 primary antibodies
  • Description
    Goat polyclonal to CLCN2
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Rabbit, Horse, Cow, Dog, Pig, Monkey, Marmoset (common)
  • Immunogen

    Synthetic peptide:


    , corresponding to internal sequence amino acids 777-789 of Human CLCN2 (NP_004357.3).

  • Positive control
    • HeLa cell lysate.


Associated products


Our Abpromise guarantee covers the use of ab99501 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 0.3 - 1 µg/ml. Detects a band of approximately 100 kDa (predicted molecular weight: 98 kDa).


  • FunctionVoltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport.
  • Tissue specificityUbiquitously expressed. Moderately expressed in aortic and coronary vascular smooth muscle cells and expressed at a low level in aortic endothelial cells.
  • Involvement in diseaseDefects in CLCN2 are associated with susceptibility to idiopathic generalized epilepsy type 11 (IGE11) [MIM:607628]. A disorder characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Generalized seizures arise diffusely and simultaneously from both hemispheres of the brain.
    Defects in CLCN2 are the cause of childhood absence epilepsy type 3 (ECA3) [MIM:607682]. ECA3 is a subtype of idiopathic generalized epilepsy (IGE) characterized by onset at age 6-7 years, frequent absence seizures (several per day) and bilateral, synchronous, symmetric 3 Hz spike waves on EEG. During adolescence, tonic-clonic and myoclonic seizures develop.
    Defects in CLCN2 are associated with juvenile absence epilepsy type 2 (JAE2) [MIM:607628]. JAE is a subtype of idiopathic generalized epilepsy (IGE) characterized by onset occurring around puberty, absence seizures, generalized tonic-clonic seizures (GTCS), GTCS on awakening and myoclonic seizures.
    Defects in CLCN2 are associated with juvenile myoclonic epilepsy type 8 (EJM8) [MIM:607628]. A subtype of idiopathic generalized epilepsy. Patients have afebrile seizures only, with onset in adolescence (rather than in childhood) and myoclonic jerks which usually occur after awakening and are triggered by sleep deprivation and fatigue.
  • Sequence similaritiesBelongs to the chloride channel (TC 2.A.49) family. ClC-2/CLCN2 subfamily.
    Contains 2 CBS domains.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • Chloride Channel 2 antibody
    • Chloride channel protein 2 antibody
    • Chloride channel, voltage sensitive 2 antibody
    • CIC 2 antibody
    • CIC2 antibody
    • ClC-2 antibody
    • CLC2 antibody
    • Clcn2 antibody
    • CLCN2_HUMAN antibody
    • ECA2 antibody
    • ECA3 antibody
    • EG13 antibody
    • EGI11 antibody
    • EGMA antibody
    • EJM6 antibody
    • EJM8 antibody
    • PKA-activated chloride channel antibody
    see all

Anti-CLCN2 antibody images

  • Anti-CLCN2 antibody (ab99501) at 0.3 µg/ml + HeLa cell lysate at 35 µg
    developed using the ECL technique

    Predicted band size : 98 kDa

References for Anti-CLCN2 antibody (ab99501)

ab99501 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab99501.
Please use the links above to contact us or submit feedback about this product.